Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

63850 1504871583HCLSReviewHongKongSeptember2017.pdf
Energy Boardroom

NICE R&D cost request sets orphan drug precedent with Soliris guidance

04.03.2014 / Scripintelligence

One way in which it differs, laid out in the HST interim process and methods statement, is that NICE will take into account what could be considered a "reasonable cost" for the medicine. NICE's methods statement specifically says this will be considered…

LATEST ISSUE

DOWNLOAD

Most Read

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: